[{"uuid": "99a55f60-06b2-336e-913c-216ac4513751", "title": "Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming\u00a0Biotech Showcase during the JP Morgan Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cellectar-biosciences-highlight-2025-strategic-230000679.html", "providerPublishTime": 1736722800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/EXHcS4nDsGWd2gMgSYTbUg--~B/aD0xNzEyO3c9MTY4ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 1688, "height": 1712, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zq_A7ZElBJOIKs.YdsTOBw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLRB"]}, {"uuid": "ee71a473-a0b6-30cd-a987-d29f2c742daf", "title": "Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/cellectar-biosciences-stock-plunges-cancer-162502647.html", "providerPublishTime": 1733934302, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/cd78fhvr_vAGrcp8s7gzwg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/8a4be95b443ec36b3d44bed682d06f8b", "width": 983, "height": 553, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/.3mYnD8glCIbR4zeNqHnUA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/8a4be95b443ec36b3d44bed682d06f8b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLRB"]}, {"uuid": "24de4f02-64a1-3e9e-93aa-6d52a66f9844", "title": "Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cellectar-biosciences-provides-strategic-clinical-220000161.html", "providerPublishTime": 1733868000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/EXHcS4nDsGWd2gMgSYTbUg--~B/aD0xNzEyO3c9MTY4ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 1688, "height": 1712, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zq_A7ZElBJOIKs.YdsTOBw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLRB"]}, {"uuid": "fa2181b3-773e-36ad-acf7-c80907bb8770", "title": "Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cellectar-biosciences-reports-financial-results-120500054.html", "providerPublishTime": 1731931500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/EXHcS4nDsGWd2gMgSYTbUg--~B/aD0xNzEyO3c9MTY4ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 1688, "height": 1712, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zq_A7ZElBJOIKs.YdsTOBw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLRB"]}, {"uuid": "d1fa6eb4-4130-362a-8dbd-187facca035b", "title": "Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cellectar-biosciences-northstar-medical-radioisotopes-130500526.html", "providerPublishTime": 1731589500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/EXHcS4nDsGWd2gMgSYTbUg--~B/aD0xNzEyO3c9MTY4ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 1688, "height": 1712, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zq_A7ZElBJOIKs.YdsTOBw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLRB"]}, {"uuid": "3cfdf1dd-ae2c-37a0-8c9a-76ebaafc26e2", "title": "Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cellectar-biosciences-report-third-quarter-210500062.html", "providerPublishTime": 1731359100, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/EXHcS4nDsGWd2gMgSYTbUg--~B/aD0xNzEyO3c9MTY4ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 1688, "height": 1712, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zq_A7ZElBJOIKs.YdsTOBw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLRB"]}, {"uuid": "1d0d240a-cafe-32a0-8d8e-ec7a20f2975d", "title": "Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cellectar-selected-present-data-phase-114000175.html", "providerPublishTime": 1730979600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Pq.TBs4PKmh_FSyMf8ETcw--~B/aD0xMTI7dz0zNjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fa4113865c027fc15f4677dd5a7eb358", "width": 362, "height": 112, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Fl90jerW90Ez35ZIZ6yJ0g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fa4113865c027fc15f4677dd5a7eb358", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLRB"]}, {"uuid": "c5fcc793-57ef-3611-85b4-1ea62d1909c2", "title": "Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cellectar-biosciences-spectronrx-partner-manufacture-130500971.html", "providerPublishTime": 1731416700, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/EXHcS4nDsGWd2gMgSYTbUg--~B/aD0xNzEyO3c9MTY4ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 1688, "height": 1712, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zq_A7ZElBJOIKs.YdsTOBw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5e6e3bb69a6bf56dab70ba270a2846a0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLRB"]}, {"uuid": "b1f19f51-f13c-3029-b4bc-9ef605f73291", "title": "NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/northstar-medical-radioisotopes-executes-supply-130000527.html", "providerPublishTime": 1732194000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/s2YVrU6jvJ3fOCQPv_Y9wA--~B/aD0yMjE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/83004d5c059a031567270ec0b405ea3a", "width": 480, "height": 221, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/bqJ0VRX4moOa4J5DiRYYzA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/83004d5c059a031567270ec0b405ea3a", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "6c6f4542-bf52-3fdf-b11d-3ac31d2f4f45", "title": "Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $14, Maintains Outperform Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/oppenheimer-adjusts-cellectar-biosciences-price-132634245.html", "providerPublishTime": 1732022794, "type": "STORY", "relatedTickers": ["CLRB"]}, {"uuid": "51ae18ae-79c2-3a09-9066-857346f0d5ab", "title": "Q3 2024 Cellectar Biosciences Inc Earnings Call", "publisher": "Thomson Reuters StreetEvents", "link": "https://finance.yahoo.com/news/q3-2024-cellectar-biosciences-inc-063955013.html", "providerPublishTime": 1731998395, "type": "STORY", "relatedTickers": ["CLRB"]}]